他莫昔芬和托瑞米芬在激素受体低表达围绝经期晚期乳腺癌中的疗效对比  

Comparison of Clinical Effect of Tamoxifen and Toremifene for Advanced Breast Cancer in Perimenopausal Period with Low Expression of Hormone Receptor

作　　者：陈宇霞[1] 杨伟雄[1] 陈翔 Chen Yuxia(Department of Galactphore surgery,Maoming People's Hospital,Maoming City,Guangdong Province,525000)

机构地区：[1]广东省茂名市人民医院乳腺病科,525000 [2]上海市宝山区中西医结合医院普外科,201999

出　　处：《黑龙江医药》2020年第6期1329-1331,共3页Heilongjiang Medicine journal

摘　　要：目的:对比分析他莫昔芬(TAM)和托瑞米芬(TOR)在激素受体低表达围绝经期晚期乳腺癌中的疗效和不良反应。方法:自2015年7月至2019年1月,入组共63例患者,随机分为观察组(30例,予他莫昔芬片10mg,1天2次)和对照组(33例,予托瑞米芬片60mg,1天1次);每2个月评估一次疗效。结果:患者的治疗时间为2~24个月,观察组中位无进展生存期(PFS)为6.5个月,对照组为7.5个月,未见统计学上有显著性差异(P>0.05)。观察组出现会阴部瘙痒、潮热的发生率比对照组高,统计学上均有显著性差异(P<0.05)。结论:TAM与TOR对于处于围绝经期的激素受体低表达的晚期乳腺癌的近期疗效相似,TOR组出现妇科不良反应少于TAM。也从另一个侧面反映三阴性乳腺癌对内分泌治疗获益更少。Objective:To compare the efficacy and side effects of tamoxifen and Toremitene in the treatment of advanced perimenopausal breast cancer with low hormone receptor expression.Methods:From July 2015 to January 2019,63 patients were randomly divided into observation group(30 cases,tamoxifen,10mg Bid)and control group(33 cases,toremifene 60mg Qd);every 2 months to evaluate the drug efficiacy.Results:The duration of treatment was 2 to 24 months.The progression-free survival(PFS)was 6.5 months in TAM group and 7.5 months in TOR group,without significant difference(P<0.05).Perineal itching and hot flashes in TAM group were higher than that in TOR group.(P<0.05).Conclusion:TAM and TOR have similar short-term effects on advanced breast cancer with low expression of hormone receptors in perimenopausal period.The gynecological adverse reaction of the short-term use of TOR is less than TAM.From the other side,it reflects that the TNBC get even less beneifits from endocrine therapy.

关 键 词：他莫昔芬 托瑞米芬 围绝经期 激素受体低表达 晚期乳腺癌 

分 类 号：R737.9[医药卫生—肿瘤]